|Joshua D. Millstone
Senior Associate Scientist, University of California, San Diego, California, United States.
|Joshua D. Millstone holds a Bachelors of Science degree in Chemistry/Biochemistry from The University of California, San Diego and is currently slated to defend his Master of Science Degree in Biochemistry from San Diego State University in early 2018. As of Fall 2017, Joshua Millstone is currently working on Post-Graduate Research and Premedical Sciences at the University of California, San Diego. Subsequent to conferral of his M.S. degree, Joshua Millstone will be continuing his education to pursue an M.D. Since conferral of his B.S. degree Joshua Millstone has acquired over ten-years of post-graduate research and education in academia and industry in the fields of Translational and Regenerative Medicine from the University of California, San Diego, San Diego State University, The Scripps Research Institute, The Genomics Institute of the Novartis Research Foundation (Novartis-GNF), and most recently held the position of Senior Associate Scientist at The Sanford Burnham Prebys/GSK Center for Translational Neuroscience and Pfizer. Prior to his matriculation to Novartis-GNF, Joshua Millstone worked at The Scripps Research Institute studying Fragile X syndrome. While at Novartis-GNF Joshua worked on lead-compound projects, primarily on mechanisms to inhibit cancer cachexia and cytokine storm syndrome; most notably through monoclonal antibody screening and the screening of low molecular weight compound libraries. While at Novartis-GNF Joshua was additionally the lead associate scientist in a project aimed at understanding the Klotho gene and the role it plays in aging and vitamin-D signaling. Joshua has presented numerous posters detailing his expertise in Cancer Biology and Translational/Regenerative Medicine, has been invited to numerous conferences, including the 4th Annual Global Precision Medicine & Biomarkers Leaders Summit in Munich, Germany. Finally, Joshua is currently slated to publish a portion of his work along with his peers from Novartis-GNF and in collaboration with Scientists at Stanford University examining the role of a novel regulator in muscle stem cell quiescence.|
|ELISA; Xenograft models and analysis; qPCR/RT-PCR; Injections and dosing (tail IV, IP, SQ, IM and PO); Western blotting; Blood collection (ROB/cardiac puncture); Stable cell lines; Tumor implantation/inoculations; HTP/HC assay design; Tissue collection: WAT/BAT, muscle, and major organs; IP/Co-IP; Cryostat tissue sectioning; MACS-based muscle stem cell preps; Histological staining/analysis; Primary/secondary tissue culture; Fluorescent/confocal microscopy; POC/PD experimental design; FACS (single and multi-level sorting/analysis); In vitro/in vivo assay design/screening; In vivo imaging (IVIS bioluminescent, CT, and ECHO MRI); RNA isolation and RNAi assays; Langendorff heart assays.|